Beilu Pharma(SZ:300016) Zheng Quan Zhi Xing·2025-07-27 16:13Core Viewpoint - The company announces the mandatory redemption of its convertible bonds ("北陆转债") at a price of 101.64 yuan per bond, effective after the market closes on August 4, 2025, due to the significant difference between the market price and the redemption price [1][2][8]. Summary by Sections Convertible Bond Basic Information - The total issuance of the convertible bonds was 500 million yuan, approved by the China Securities Regulatory Commission [2]. - The bonds were issued on December 11, 2020, with a conversion period from June 11, 2021, to December 6, 2026 [2][3]. Conditional Redemption Terms - The company has the right to redeem the bonds if the stock price exceeds 130% of the conversion price for 15 out of 30 consecutive trading days [7][8]. - The current conversion price is 7.02 yuan per share, and the threshold for triggering redemption is 9.13 yuan per share [8]. Redemption Implementation - The redemption price is set at 101.64 yuan per bond, which includes accrued interest [9][10]. - The bonds will stop trading on July 31, 2025, and the conversion will cease on August 5, 2025 [10]. - The redemption will be executed for all bondholders registered by the close of trading on August 4, 2025 [10]. Shareholder Actions and Compliance - The company confirms that there have been no transactions in the bonds by major shareholders or executives in the six months prior to the redemption conditions being met [10]. - Bondholders must process conversion requests through their respective securities firms [12].